1vjy: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
[[Image:1vjy.gif|left|200px]] | [[Image:1vjy.gif|left|200px]] | ||
'''Crystal Structure of a Naphthyridine Inhibitor of Human TGF-beta Type I Receptor''' | {{Structure | ||
|PDB= 1vjy |SIZE=350|CAPTION= <scene name='initialview01'>1vjy</scene>, resolution 2.0Å | |||
|SITE= | |||
|LIGAND= <scene name='pdbligand=460:2-[5-(6-METHYLPYRIDIN-2-YL)-2,3-DIHYDRO-1H-PYRAZOL-4-YL]-1,5-NAPHTHYRIDINE'>460</scene> | |||
|ACTIVITY= [http://en.wikipedia.org/wiki/Non-specific_serine/threonine_protein_kinase Non-specific serine/threonine protein kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.1 2.7.11.1] | |||
|GENE= | |||
}} | |||
'''Crystal Structure of a Naphthyridine Inhibitor of Human TGF-beta Type I Receptor''' | |||
==Overview== | ==Overview== | ||
Line 7: | Line 16: | ||
==Disease== | ==Disease== | ||
Known diseases associated with this structure: | Known diseases associated with this structure: Loeys-Dietz syndrome, type 1A OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=190181 190181]], Loeys-Dietz syndrome, type 2A OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=190181 190181]] | ||
==About this Structure== | ==About this Structure== | ||
1VJY is a [ | 1VJY is a [[Single protein]] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1VJY OCA]. | ||
==Reference== | ==Reference== | ||
Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors., Gellibert F, Woolven J, Fouchet MH, Mathews N, Goodland H, Lovegrove V, Laroze A, Nguyen VL, Sautet S, Wang R, Janson C, Smith W, Krysa G, Boullay V, De Gouville AC, Huet S, Hartley D, J Med Chem. 2004 Aug 26;47(18):4494-506. PMID:[http:// | Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors., Gellibert F, Woolven J, Fouchet MH, Mathews N, Goodland H, Lovegrove V, Laroze A, Nguyen VL, Sautet S, Wang R, Janson C, Smith W, Krysa G, Boullay V, De Gouville AC, Huet S, Hartley D, J Med Chem. 2004 Aug 26;47(18):4494-506. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/15317461 15317461] | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
[[Category: Non-specific serine/threonine protein kinase]] | [[Category: Non-specific serine/threonine protein kinase]] | ||
Line 39: | Line 48: | ||
[[Category: transferase]] | [[Category: transferase]] | ||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Mar 20 14:46:37 2008'' |
Revision as of 15:46, 20 March 2008
| |||||||
, resolution 2.0Å | |||||||
---|---|---|---|---|---|---|---|
Ligands: | |||||||
Activity: | Non-specific serine/threonine protein kinase, with EC number 2.7.11.1 | ||||||
Coordinates: | save as pdb, mmCIF, xml |
Crystal Structure of a Naphthyridine Inhibitor of Human TGF-beta Type I Receptor
OverviewOverview
Optimization of the screening hit 1 led to the identification of novel 1,5-naphthyridine aminothiazole and pyrazole derivatives, which are potent and selective inhibitors of the transforming growth factor-beta type I receptor, ALK5. Compounds 15 and 19, which inhibited ALK5 autophosphorylation with IC50 = 6 and 4 nM, respectively, showed potent activities in both binding and cellular assays and exhibited selectivity over p38 mitogen-activated protein kinase. The X-ray crystal structure of 19 in complex with human ALK5 is described, confirming the binding mode proposed from docking studies.
DiseaseDisease
Known diseases associated with this structure: Loeys-Dietz syndrome, type 1A OMIM:[190181], Loeys-Dietz syndrome, type 2A OMIM:[190181]
About this StructureAbout this Structure
1VJY is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.
ReferenceReference
Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors., Gellibert F, Woolven J, Fouchet MH, Mathews N, Goodland H, Lovegrove V, Laroze A, Nguyen VL, Sautet S, Wang R, Janson C, Smith W, Krysa G, Boullay V, De Gouville AC, Huet S, Hartley D, J Med Chem. 2004 Aug 26;47(18):4494-506. PMID:15317461
Page seeded by OCA on Thu Mar 20 14:46:37 2008
Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)
OCA- Pages with broken file links
- Homo sapiens
- Non-specific serine/threonine protein kinase
- Single protein
- Boullay, V.
- Fouchet, M H.
- Gellibert, F.
- Goodland, H.
- Gouville, A C.de.
- Hartley, D.
- Huet, S.
- Janson, C.
- Krysa, G.
- Laroze, A.
- Lovegrove, V.
- Mathews, N.
- Nguyen, V L.
- Sautet, S.
- Smith, W.
- Wang, R.
- Woolven, J.
- 460
- Inhibitor complex
- Protein kinase
- Transferase